Targeted Medical (TRGM) 0.2700 $TRGM
Targeted Medical Pharma, Inc. - "Targeted Medical Pharma Third Quarter Recap"
ACCESSWIRE - Wed Dec 03, 2:01PM CST
NEW YORK, NY / ACCESSWIRE / December 3, 2014 / Targeted Medical Pharma, Inc. (OTCQB: TRGM) today published a new blog post on The Chairman's Blog, written by the Company's CEO and CSO, Dr. William Shell. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Targeted Medical Pharma Inc. "Treatment Update: Medical Foods for the Treatment of PTSD"
ACCESSWIRE - Mon Nov 03, 7:16AM CST
New York, NY / ACCESSWIRE / November 3, 2014 / Targeted Medical Pharma, Inc. (OTCQB: TRGM) today published a new blog post on The Chairman's Blog, written by the Company's CEO and CSO, Dr. William Shell. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Targeted Medical Pharma Releases Promising Trial Results for the Treatment of Posttraumatic Stress Disorder
Business Wire - Mon Oct 13, 5:00PM CDT
Targeted Medical Pharma, Inc. (OTCQB: TRGM), a drug discovery and development company, today announced the results of a clinical trial studying the amino acid based medical foods, Sentra AM and Sentra PM in Veterans suffering from symptoms associated with Posttraumatic Stress Disorder (PTSD).
Targeted Medical Pharma - "Developing New Therapies for Chronic Pain"
ACCESSWIRE - Tue Oct 07, 8:24AM CDT
New York, NY / October 7, 2014 / Targeted Medical Pharma, Inc. (OTCQB: TRGM) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Operating Officer, Dr. David Silver. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Targeted Medical Pharma's New Approach to Pain Management Targets Epidemic of Opioid and NSAID Over-Prescribing
Business Wire - Mon Oct 06, 5:00PM CDT
Targeted Medical Pharma, Inc. (OTCQB: TRGM) recently published the White Paper: Innovations in Pain Management discussing the epidemic of pain, the dangers of commonly prescribed pain medications and the benefits of Theramine as a clinically effective alternative to opioids and nonsteroidal anti-inflammatory (NSAID) drugs for the management of back pain and inflammation.
Targeted Medical Pharma to Present at Sachs Associated 14th Annual Biotech in Europe Forum for Global Partnering and Investment
Business Wire - Tue Sep 16, 9:00AM CDT
Targeted Medical Pharma (OTCQB:TRGM), today announced that William Shell, M.D., Chairman, CSO and CEO is scheduled to present the latest company information regarding the advances in therapeutic nutrition and medical foods technology, at the 14th Annual Biotech in Europe Forum at the Congress Center in Basel, Switzerland. The presentation is scheduled for September 30th, 2014 at 11:45 am in the Lima Room. Dr. Shell will also be a panelist in the discussion regarding advancements in Neuroscience at 3:30 pm.
Targeted Medical Pharma, Inc. - "Welcome to the Targeted Medical Pharma Blog"
ACCESSWIRE - Mon Sep 15, 8:31AM CDT
New York, NY / September 15, 2014 / Targeted Medical Pharma, Inc. (OTCQB: TRGM) today published a new blog post on The Chairman's Blog, written by the Company's CEO and CSO, Dr. William Shell. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Targeted Medical Pharma Reports Second Quarter 2014 Financial Results
Business Wire - Thu Aug 14, 4:30PM CDT
Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced financial results for its second quarter ended June 30, 2014. The Company posted increased revenues, gross profit and an increase in net income before interest, taxes, depreciation and amortization, and stock based compensation (Adjusted EBITDA*) on a quarter-over-quarter basis.
Targeted Medical Pharma Agrees to Sponsor a Clinical Trial Conducted by the United States Army and Henry M. Jackson Foundation for the Advancement of Military Medicine
Business Wire - Mon Jul 28, 10:21AM CDT
Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the completion of an agreement to sponsor an investigator-initiated study with the United States Army and The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. (HJF). The study, which is slated to start enrolling patients in Q2 of 2014, will involve the Company's medical food Theramine.
Tauriga Sciences enters into license agreement with Targeted Medical Pharma for launch of new cannabis complements product line
M2 - Thu Jul 17, 8:15AM CDT
Life sciences company Tauriga Sciences (Other OTC:TAUG) disclosed on Wednesday the launch of a non-exclusive licensing agreement under its "Cannabis Complements" product line.
Tauriga Sciences Inc. Signs License Agreement With Targeted Medical Pharma Inc.
GlobeNewswire - Wed Jul 16, 2:31PM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or the "Company"
, a diversified life sciences company, announced today it has signed a non-exclusive licensing agreement with Targeted Medical Pharma Inc. (OTCQB:TRGM) to reformulate and rebrand Targeted Medical's medical food formulations into dietary supplements as part of Tauriga's "Cannabis Complements" product line. Tauriga's new Cannabis Complements product line will be formally launched later in the summer and consists of dietary supplements and other natural wellness products that do not contain cannabis oil and that will attempt to address cannabis-related effects, such as anxiety, memory and cognitive functions, and appetite control. The products to be offered under the "Cannabis Complements" line will contain "GRAS" ingredients, the U.S. Food and Drug Administration's designation for ingredients that are "Generally Recognized as Safe".
Targeted Medical Pharma Appoints Two New Independent Members to the Board of Directors
Business Wire - Thu Jun 12, 5:00PM CDT
Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the addition of two independent members to the Company's board of directors. The Company welcomes back health care specialist Kerry Weems to the board as an independent director and chairman of the Nominating and Governance Committee, as well as corporate finance expert Paul Pelosi, Jr. as an independent director.
Targeted Medical Pharma, Inc. - "Targeted Medical Pharma Third Quarter Recap"
ACCESSWIRE - Wed Dec 03, 2:01PM CST
NEW YORK, NY / ACCESSWIRE / December 3, 2014 / Targeted Medical Pharma, Inc. (OTCQB: TRGM) today published a new blog post on The Chairman's Blog, written by the Company's CEO and CSO, Dr. William Shell. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Targeted Medical Pharma Inc. "Treatment Update: Medical Foods for the Treatment of PTSD"
ACCESSWIRE - Mon Nov 03, 7:16AM CST
New York, NY / ACCESSWIRE / November 3, 2014 / Targeted Medical Pharma, Inc. (OTCQB: TRGM) today published a new blog post on The Chairman's Blog, written by the Company's CEO and CSO, Dr. William Shell. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Targeted Medical Pharma Releases Promising Trial Results for the Treatment of Posttraumatic Stress Disorder
Business Wire - Mon Oct 13, 5:00PM CDT
Targeted Medical Pharma, Inc. (OTCQB: TRGM), a drug discovery and development company, today announced the results of a clinical trial studying the amino acid based medical foods, Sentra AM and Sentra PM in Veterans suffering from symptoms associated with Posttraumatic Stress Disorder (PTSD).
Targeted Medical Pharma - "Developing New Therapies for Chronic Pain"
ACCESSWIRE - Tue Oct 07, 8:24AM CDT
New York, NY / October 7, 2014 / Targeted Medical Pharma, Inc. (OTCQB: TRGM) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Operating Officer, Dr. David Silver. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Targeted Medical Pharma's New Approach to Pain Management Targets Epidemic of Opioid and NSAID Over-Prescribing
Business Wire - Mon Oct 06, 5:00PM CDT
Targeted Medical Pharma, Inc. (OTCQB: TRGM) recently published the White Paper: Innovations in Pain Management discussing the epidemic of pain, the dangers of commonly prescribed pain medications and the benefits of Theramine as a clinically effective alternative to opioids and nonsteroidal anti-inflammatory (NSAID) drugs for the management of back pain and inflammation.
Targeted Medical Pharma to Present at Sachs Associated 14th Annual Biotech in Europe Forum for Global Partnering and Investment
Business Wire - Tue Sep 16, 9:00AM CDT
Targeted Medical Pharma (OTCQB:TRGM), today announced that William Shell, M.D., Chairman, CSO and CEO is scheduled to present the latest company information regarding the advances in therapeutic nutrition and medical foods technology, at the 14th Annual Biotech in Europe Forum at the Congress Center in Basel, Switzerland. The presentation is scheduled for September 30th, 2014 at 11:45 am in the Lima Room. Dr. Shell will also be a panelist in the discussion regarding advancements in Neuroscience at 3:30 pm.
Targeted Medical Pharma, Inc. - "Welcome to the Targeted Medical Pharma Blog"
ACCESSWIRE - Mon Sep 15, 8:31AM CDT
New York, NY / September 15, 2014 / Targeted Medical Pharma, Inc. (OTCQB: TRGM) today published a new blog post on The Chairman's Blog, written by the Company's CEO and CSO, Dr. William Shell. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Targeted Medical Pharma Reports Second Quarter 2014 Financial Results
Business Wire - Thu Aug 14, 4:30PM CDT
Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced financial results for its second quarter ended June 30, 2014. The Company posted increased revenues, gross profit and an increase in net income before interest, taxes, depreciation and amortization, and stock based compensation (Adjusted EBITDA*) on a quarter-over-quarter basis.
Targeted Medical Pharma Agrees to Sponsor a Clinical Trial Conducted by the United States Army and Henry M. Jackson Foundation for the Advancement of Military Medicine
Business Wire - Mon Jul 28, 10:21AM CDT
Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the completion of an agreement to sponsor an investigator-initiated study with the United States Army and The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. (HJF). The study, which is slated to start enrolling patients in Q2 of 2014, will involve the Company's medical food Theramine.
Tauriga Sciences enters into license agreement with Targeted Medical Pharma for launch of new cannabis complements product line
M2 - Thu Jul 17, 8:15AM CDT
Life sciences company Tauriga Sciences (Other OTC:TAUG) disclosed on Wednesday the launch of a non-exclusive licensing agreement under its "Cannabis Complements" product line.
Tauriga Sciences Inc. Signs License Agreement With Targeted Medical Pharma Inc.
GlobeNewswire - Wed Jul 16, 2:31PM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or the "Company"
, a diversified life sciences company, announced today it has signed a non-exclusive licensing agreement with Targeted Medical Pharma Inc. (OTCQB:TRGM) to reformulate and rebrand Targeted Medical's medical food formulations into dietary supplements as part of Tauriga's "Cannabis Complements" product line. Tauriga's new Cannabis Complements product line will be formally launched later in the summer and consists of dietary supplements and other natural wellness products that do not contain cannabis oil and that will attempt to address cannabis-related effects, such as anxiety, memory and cognitive functions, and appetite control. The products to be offered under the "Cannabis Complements" line will contain "GRAS" ingredients, the U.S. Food and Drug Administration's designation for ingredients that are "Generally Recognized as Safe". Targeted Medical Pharma Appoints Two New Independent Members to the Board of Directors
Business Wire - Thu Jun 12, 5:00PM CDT
Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the addition of two independent members to the Company's board of directors. The Company welcomes back health care specialist Kerry Weems to the board as an independent director and chairman of the Nominating and Governance Committee, as well as corporate finance expert Paul Pelosi, Jr. as an independent director.
